The tissue distribution of NMO-IgG was determined at 1 and 24 hours after intravenous administration, in which tissues were fixed and immunostained for AQP4 using an anti-AQP4 antibody and for NMO-IgG using an anti-human IgG fluorescent secondary antibody. The gene discussed is AQP4; the disease is neuromyelitis optica.